Aduro BioTech Receives Breakthrough Therapy Designation from FDA for Innovative Pancreatic Cancer Combination Immunotherapy

FDA Breakthrough Designation Highlights Aduro’s Immunotherapeutic Approach as Promising Treatment for Patients with Pancreatic Cancer July 21, 2014 Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its pancreatic cancer combination treatment that consists of its CRS-207 and GVAX Pancreas immunotherapies. According to the FDA, a …